Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
David Apelian Sylvia Wheeler Aljanae Reynolds Progeroid Laminopathies Company Annual Report On Form Prnewswire Eiger Biopharmaceuticals Inc
Source: prnewswire.com